

Dopamine agonists in prolactinoma

Table S5. Sex steroids before and after treatment with dopamine receptor antagonists in patients with prolactinomas.

Study (Ref.nr.)	Testosterone baseline, nmol/L (SD)	Estradiol or estrogen baseline (SD)	Estradiol or estrogen at follow-up (SD)	FSH baseline, IU/L (SD)	FSH at follow-up, IU/L (SD)	LH baseline, IU/L (SD)	LH at follow-up, IU/L (SD)	Hypogonadism, %	Estrogen- or testosterone replacement at baseline (n)
Schwetz (25)	6.7 (1.0)	20.7 (16.7) ¹	51.1 (18) ¹	4.43 (3.33)	5.28 (4.67)	1.8 (1.78)	2.18 (2.44)	72	-
Auriemma II (26)	7.5 (4.6)	-	-	-	-	-	-	69	0
Medic (31)	-	-	-	-	-	-	-	95	-
Pala (27)	-	52.7 (24.3) ¹	63.4 (167.4) ¹	5.7 (2.6)	5.8 (1.8)	5.3 (4.4)	5.2 (1.5)	72	-
Barbosa (33)	-	-	-	-	-	-	-	63 (F), 100 (M)	-
Auriemma (5)	-	-	-	-	-	-	-	-	-
Ciresi (4)	-	-	-	-	-	-	-	-	-
Inancli (29)	-	-	-	-	-	-	-	-	-
Berinder (6)	4.6 (2.3)	-	-	-	-	-	-	100	50 (F), 33 (M)
Silva (8)	-	-	-	-	-	-	-	74	-
Serri (7)	-	-	-	-	-	-	-	100	0
Yavuz (28)	-	50.1 (19.2) ²	129.9 (60.8) ²	-	-	-	-	44	-
Doknic (30)	-	-	-	-	-	-	-	-	-
Iglesias (32)	9.2 (5.6)	-	-	2.15 (1.19)	2.75 (1.93)	1.9 (1.78)	2.73 (2.3)	-	-

(-) Not reported

M: Male

F: Female

¹ nmol/ L

² ng/ mL